# How to Read ClinicalTrials.gov for Due Diligence: A Healthcare Investor's Field Guide > ClinicalTrials.gov contains layered signals that separate credible drug and device programs from promotional noise. This guide shows investors exactly which fields to interrogate, what red flags look like, and how to cross-reference with FDA, SEC, and PubMed records. ## Why ClinicalTrials.gov Is the Starting Point for Any Clinical-Stage Investment ClinicalTrials.gov is the U.S. federal registry mandated under the FDA Amendments Act of 2007. Every interventional trial of a drug, biologic, or device that is conducted in the United States, or that supports a U.S. marketing application, must be registered here. That legal obligation means the data is harder to sanitize than a press release or investor deck. For healthcare investors, the registry is not a secondary check. It is the primary document. The single most important habit is to read the registry record before reading any company communication about that trial. What the company says and what the registry says should match. When they diverge, that divergence is itself the signal. ## What Does Each Section of a ClinicalTrials.gov Record Actually Tell You? Every record is organized into standardized modules. The ones that matter most for due diligence are: **Study Title and NCT Number.** The NCT number is the permanent, immutable identifier. Use it to track every version of the record over time using the History of Changes tab. Companies sometimes quietly alter endpoints, sample sizes, or completion dates without issuing a press release. The change log exposes this. **Sponsor and Collaborators.** Verify who is actually running the trial. A small sponsor with a large academic collaborator listed prominently can signal that the academic center is doing the scientific heavy lifting, which is a positive indicator. A contract research organization listed as the responsible party with no named principal investigator is a yellow flag worth investigating. **Study Status.** The vocabulary here is precise. Recruiting means enrollment is active. Active, not recruiting means patients are enrolled but follow-up continues. Terminated is the most consequential word in the registry. Always click through to the Why Study Stopped field. Regulatory agencies, not companies, determine whether a termination was for safety or futility. Companies often describe terminations as strategic or due to enrollment challenges. The registry sometimes tells a different story. **Primary and Secondary Endpoints.** These are the legal commitments the sponsor made before seeing data. Investors should record the primary endpoint on the registration date, then compare it to what the company reports as the primary endpoint at data readout. Endpoint switching, moving from a hard clinical outcome to a surrogate, or from a prespecified timepoint to a different one, is one of the most common forms of selective reporting in clinical-stage biotech. **Enrollment Numbers and Timeline.** Compare planned enrollment versus actual enrollment at each update. Chronic under-enrollment is the leading predictor of trial failure and extension. Use the estimated completion date history, visible in the change log, to see how many times the date has been pushed. **Eligibility Criteria.** Narrow inclusion criteria can make a trial easier to run but limit the addressable market at approval. Very tight criteria, such as a specific mutation prevalence or prior treatment requirement, can shrink a theoretical patient population by 80 percent or more. Model this before forming a position. **Outcome Measures.** Distinguish between primary and secondary outcomes, and between outcomes listed at registration versus outcomes added later. Post-hoc outcomes added after data collection begins carry almost no evidential weight. ## How Do You Cross-Reference ClinicalTrials.gov with Other Primary Sources? The registry is most powerful when layered against three other sources. First, check the FDA. For any trial supporting a U.S. marketing application, the FDA's public database of approved drugs (Drugs@FDA) and the 510(k) and PMA databases for devices will show whether the agency agreed with the sponsor's endpoint and population definitions. Advisory committee briefing documents, which are publicly posted, often contain the FDA's own statistical review of trial data and will flag endpoint switching or protocol amendments the company never disclosed publicly. Second, check SEC EDGAR. For publicly traded sponsors, every material amendment to a trial protocol should appear in an 8-K. If you find protocol changes in the ClinicalTrials.gov change log that never appeared in SEC filings, that is a disclosure gap worth raising. Third, check PubMed. A trial that has completed but has no published results after 24 months is statistically more likely to have produced negative or ambiguous findings. Publication bias is well-documented. Absence of a publication is a data point. ## What Are the Most Common Mistakes Investors Make Reading This Registry? The most frequent error is reading only the current snapshot of a record without checking the change history. A trial can appear clean today while having a record of four endpoint changes and three enrollment extensions in its past. The second mistake is accepting company descriptions of trial design without verifying the registered protocol. Phrases like pivotal trial and Phase 3 have specific regulatory meanings. Confirm that the trial's registered phase, design, and intended regulatory use match what the company is claiming in its communications. The third mistake is ignoring results postings. Under federal law, most trials must post summary results within 12 months of the primary completion date. If results are overdue, the sponsor is in violation of the law and the data is likely unfavorable. ## Due Diligence Checklist for ClinicalTrials.gov - Pull the NCT number and open the History of Changes tab before reading anything else - Record the primary endpoint and primary completion date as of registration - Count the number of protocol amendments and note the dates - Check Study Status and read the Why Study Stopped field if applicable - Compare planned versus actual enrollment across all updates - Confirm results are posted if the primary completion date is more than 12 months past - Cross-reference protocol amendments against SEC 8-K filings on EDGAR - Search PubMed for published results and compare published endpoints to registered endpoints - Check the FDA database for any agency communications about the program ## How Can You Automate This Process? Manually tracking change logs across a portfolio of clinical-stage companies is slow and error-prone. MedFuel Intel uses AI-driven analysis to monitor ClinicalTrials.gov records continuously, flag endpoint changes, track enrollment velocity, and cross-reference registry data against SEC filings, FDA databases, and PubMed in a single structured report. Run a free Red Flag Screener on any clinical-stage company at https://medfuelintel.com and get a primary-source-verified summary in minutes. --- *Informational only, not investment advice.* --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/how-to-read-clinicaltrials-gov-for-due-diligence). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.